ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (PRQR) showed zero cyber incidents and zero red-flag 8-K filings in the past 90 days, suggesting operational stability in the near term. However, low signal in our window doesn't mean low risk; biotech companies face persistent dilution and financing pressures that a 90-day snapshot won't capture. The full $49 Report pulls 12 months of 8-K context, maps the complete financing history, flags dilution risk scores, and surfaces AI-detected risk signals across management, clinical programs, and capital structure. This adds the depth needed to assess whether PRQR's runway and cash burn align with its clinical timeline and shareholder interests.